Research letter
Tofacitinib for the treatment of alopecia areata in preadolescent children

https://doi.org/10.1016/j.jaad.2018.08.041Get rights and content

First page preview

First page preview
Click to open first page preview

References (5)

There are more references available in the full text version of this article.

Cited by (47)

  • Clinical response to oral tofacitinib in pediatric patients with alopecia areata

    2023, JAAD Case Reports
    Citation Excerpt :

    Studies investigating its use for pediatric AA are scarce. Craiglow et al reported positive outcomes with 5 mg oral tofacitinib twice a day for pediatric AA.10 Our patient population was equally distributed with respect to sex but substantially varied in terms of AA onset (as early as the age of 4 years, latest onset at the age of 14 years), disease subtype (5/10 patchy AA, 1/10 AT, 1/10 ophiasis, 3/10 AU) and severity (SALT scores ranging from 40% to 100%), and eyebrow (6/10) and eyelash involvement (7/10).

  • Treatment of pediatric alopecia areata: A systematic review

    2022, Journal of the American Academy of Dermatology
    Citation Excerpt :

    Clinical trials are currently evaluating the efficacy of tofacitinib to treat AA in adults.99 Six case series and reports evaluated systemic tofacitinib for the treatment of AA in 28 pediatric patients.95-100 Of these patients, 82% showed complete or partial response and all nonresponders were patients with AU.

  • Alopecia Areata: New Treatment Options Including Janus Kinase Inhibitors

    2021, Dermatologic Clinics
    Citation Excerpt :

    This was supported by another study that treated eight adolescents aged 12 to 19 with tofacitinib (5 mg twice a day) for a range of 5 to 18 months, yielding greater than 50% regrowth in scalp hair in all patients by 5 months.24 As for pediatric patients, Craiglow and King25 reported success treating four pediatric patients 8 to 10 years old with oral tofacitinib (5 mg twice a day) for a range of 6 to 15 months, with three of the four patients showing significant regrowth, and two of which showed complete regrowth by 6 months. In addition, baricitinib, a JAK 1 and 2 inhibitor, is another drug that has been used to treat AA.

View all citing articles on Scopus

Funding sources: Dr King received support from the Ranjini and Ajay Poddar Resource Fund for Dermatologic Diseases Research.

Disclosure: Dr Craiglow has served on advisory boards, received honoraria from, and is a consultant to Pfizer. Dr King has served on advisory boards for Pfizer and Aclaris Therapeutics and is a consultant to Pfizer, Concert Pharmaceuticals, and Eli Lilly and Company.

View full text